Alparslan SERARSLAN, Zeynep ÖZSARAN, Senem ALANYALI, Ayşe ALTINOK, Ayfer AY EREN, Evrim METCALFE, Özgür ALTMIŞDÖRTOĞLU, Müge AKMANSU, Nuran BEŞE, Hüseyin TEPETAM, Pelin ALTINOK, Bilge GÜRSEL, Şefika Arzu ERGEN

Postmastectomy Radiotherapy Decision for Patients without Lymph Node Metastases: Turkish Radiation Oncology Society Breast Cancer Working Group

OBJECTIVERecent meta-analysis have not revealed any positive effects of postmastectomy radiotherapy (PMRT)on locoregional recurrence (LRR) or overall survival in axilla-negative patients. However, risk of LRRincreases to 15% in the presence of two or more adverse factors for the same patient group. In this study,PMRT indications and volume selections of radiation oncologists in Turkey for axilla-negative breastcancer was investigated.METHODSQuestionnaires were distributed to members of the breast cancer study group. Data of patients with axillary negative or isolated/micrometastasis and PMRT over 10 years (2006–2016) were collected from 10participating centers. Clinical and tumor histopathological features and treatment details of 185 patientswere analyzed.RESULTSThe median age of patients was 48 years. Ratio of early-stage patients was 60% (T1-15%,T2-45%). Therewere 147 (79%) negative cases, 32 (17%) with micrometastasis, and 6 (3%) with isolated tumor cells.Half of the patients had only their chest walls (CW) irradiated. Peripheral lymphatics were also includedin the rest. In Nmic cases, ratio of irradiation of supraclavicular and axillary lymph nodes with CW werestatistically significant compared to CW irradiation (72% and 28%, respectively; p=0.015).CONCLUSIONConsidering the low number of patients treated over 10 years in 10 different centers in Turkey, it can besaid that PMRT is often done in node-negative breast cancer. It is difficult to reach a definite conclusionfor patients with Nmic, due to lack of data from patients with PMRT. However, the general tendency isto irradiate peripheral lymphatics in Nmic cases if PMRT is to be performed.

PDF

___

1. Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 2003;21(7):1205–13.
2. Yıldırım E, Berberoğlu U. Can a subgroup of nodenegative breast carcinoma patients with T1–2 tumour who may benefit from postmastectomy radiotherapy be identified? Int J Radiat Oncol Biol Phys 2007;68(4):1024–9.
3. Truong PT, Lesperance M, Culhaci A, Kader HA, Speers CH, Olivotto IA. Patient Subsets with T1-T2, Node-Negative Breast Cancer at High Locoregional Recurrence Risk After Mastectomy. Int J Radiat Oncol Biol Phys 2005;62(1):175–82.
4. Rowel N. Radiotherapy to the chest wall following mastectomy for node-negative breast cancer: A systematic review. Radiother Oncol 2009;91(1):23–32.
5. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366(9503):2087–106.
6. EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20- year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383(9935):2127–35.
7. Headon HL, Kasem A, Mokbel K. The Oncological Safety of Nipple-Sparing Mastectomy: A Systematic Review of the Literature with a Pooled Analysis of 12,358 Procedures. Arch Plast Surg 2016;43(4):328– 38.
8. Marta GN, Poortmans PM, Buchholz TA, Hijal T. Postoperative Radiation Therapy after Nipple-Sparing or Skin-Sparing Mastectomy: A Survey of European, North American, and South American Practices. Breast J 2017;23(1):26–33.
9. Truong PT, Olivotto IA, Whelan TJ, Levine M; Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ 2004;170(8):1263–73.
10.Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol 2006;24(24):3927– 32.
11.Shaikh Jr MP, Alite Jr F, Wu MJ, Altoos T, Jacobson GM. Postmastectomy Radiation Therapy for Node Negative Breast Cancer with Tumor Size of Five Centimeter or More: A Meta-analysis. Int J Radiat Oncol Biol Phys 2017;99(Suppl 2):5.
12.Truong PT, Yong CM, Abnousi F, Lee J, Kader HA, Hayashi A, et al. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy. J Am Coll Surg 2005;200(6):912–21.
13.Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 2013;139(2):539– 52.
14.Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012;23(Suppl 6):7–12.
15.Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011;29(21):2852–8.
16.Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinelnode micrometastases (IBCSG 23-01): 10-year followup of a randomised, controlled phase 3 trial. Lancet Oncol 2018;19(10):1385–93.
17.Solá M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol 2013;20(1):120–7.
18.Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. IBCSG 23-01 randomised controlled trial comparing axillary dissection versus no axillary dissection in patients with sentinel node micrometastases. Lancet Oncol 2013;14(4):297–305.
19. van Roozendaal LM, de Wilt JH, van Dalen T, van der Hage JA, Strobbe LJ, Boersma LJ, et al. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07). BMC Cancer 2015;15:610.
20.Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014;15(12):1303–10.
21.Mamtani A, Patil S, Stempel M, Morrow M. Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer. Ann Surg Oncol 2017;24(8):2182–8.
22.Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol 2004;22(21):4247–54.